
Margherita Rimini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9598009/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development. Expert Opinion on Investigational Drugs, 2022, 31, 483-494.	1.9	2
2	Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy. Journal of Chemotherapy, 2022, 34, 543-549.	0.7	1
3	Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. European Journal of Cancer, 2022, 171, 232-241.	1.3	7
4	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. Clinical and Translational Gastroenterology, 2021, 12, e00286.	1.3	15
5	Lenvatinib versus sorafenib in firstâ€line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis. Liver International, 2021, 41, 1389-1397.	1.9	45
6	Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3665-3671.	1.2	12
7	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. Hepatology Research, 2021, 51, 796-802.	1.8	4
8	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. Hpb, 2021, 23, 915-920.	0.1	14
9	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	1.9	18
10	Lenvatinib versus Sorafenib as firstâ€line treatment in hepatocellular carcinoma: A multiâ€institutional matched caseâ€control study. Hepatology Research, 2021, 51, 1229-1241.	1.8	33
11	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Targeted Oncology, 2021, 16, 653-661.	1.7	0
12	Cholangiocarcinoma: new perspectives for new horizons. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1367-1383.	1.4	13
13	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer Management and Research, 2021, Volume 13, 9379-9389.	0.9	31
14	Child Pugh and ALBI grade: past, present or future?. Annals of Translational Medicine, 2020, 8, 1044-1044.	0.7	5